Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study

Authors: Alexandra Kautzky-Willer, Kathrin Stich, Juliane Hintersteiner, Alexander Kautzky, Majid Reza Kamyar, Johannes Saukel, Julienne Johnson, Rosa Lemmens-Gruber

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

Little is known about the impact of sex-specific differences in the management of type 1 diabetes (T1DM).
Thus, we evaluated the influence of gender on risk factors, complications, clinical care and adherence in patients with T1DM.

Methods

In a cross-sectional study, sex-specific disparities in glycaemic control, cardiovascular risk factors, diabetic complications, concomitant medication use and adherence to treatment recommendations were evaluated in 225 consecutive patients (45.3% women) who were comparable with respect to age, diabetes duration, and body mass index.

Results

Although women with T1DM had a higher total cholesterol than men, triglycerides were higher in obese men and males with HbA1c>7% than in their female counterparts. No sex differences were observed in glycaemic control and in micro- or macrovascular complications. However, the subgroup analysis showed that nephropathy was more common in obese men, hyperlipidaemic women and all hypertensive patients, whereas peripheral neuropathy was more common in hyperlipidaemic women. Retinopathy was found more frequently in women with HbA1c>7%, obese men and in both sexes with a long duration of diabetes. The multivariate analysis revealed that microvascular complications were associated with the duration of disease and BMI in both sexes and with hyperlipidaemia in males. The overall adherence to interventions according to the guidelines was higher in men than in women. This adherence was concerned particularly with co-medication in patients diagnosed with hypertension, aspirin prescription in elderly patients and the achievement of target lipid levels following the prescription of statins.

Conclusions

Our data showed sex differences in lipids and overweight in patients with T1DM. Although glycaemic control and the frequency of diabetic complications were comparable between the sexes, the overall adherence to guidelines, particularly with respect to the prescription of statins and aspirin, was lower in women than in men.
Appendix
Available only for authorised users
Literature
1.
Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G: Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet. 2009, 373 (9680): 2027-2033. 10.1016/S0140-6736(09)60568-7.CrossRefPubMed
2.
Gale EA, Gillespie KM: Diabetes and gender. Diabetologia. 2001, 44 (1): 3-15. 10.1007/s001250051573.CrossRefPubMed
3.
Szalat A, Raz I: Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab. 2008, 10 (12): 1135-1156.PubMed
4.
Kautzky-Willer A, Handisurya A: Metabolic diseases and associated complications: sex and gender matter!. Eur J Clin Invest. 2009, 39 (8): 631-648. 10.1111/j.1365-2362.2009.02161.x.CrossRefPubMed
5.
Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, Fuller JH: Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB prospective complications study. Diabetes Care. 2004, 27 (2): 530-537. 10.2337/diacare.27.2.530.CrossRefPubMed
6.
Soedamah-Muthu SS, Chaturvedi N, Pickup JC, Fuller JH: Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB prospective complications study (PCS). Diabetologia. 2008, 51 (3): 493-501. 10.1007/s00125-007-0905-8.PubMedCentralCrossRefPubMed
7.
Gerstl EM, Rabl W, Rosenbauer J, Grobe H, Hofer SE, Krause U, Holl RW: Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr. 2008, 167 (4): 447-453. 10.1007/s00431-007-0586-9.CrossRefPubMed
8.
Kamyar M, Johnson BJ, McAnaw JJ, Lemmens-Gruber R, Hudson SA: Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus. Pharm World Sci. 2008, 30 (1): 120-127.CrossRefPubMed
9.
Kautzky-Willer A, Kamyar MR, Gerhat D, Handisurya A, Stemer G, Hudson S, Luger A, Lemmens-Gruber R: Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. Gend Med. 2010, 7 (6): 571-583. 10.1016/j.genm.2010.12.001.CrossRefPubMed
10.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012, 33 (13): 1635-1701.CrossRefPubMed
11.
World Health Organisation Department of Noncommunicable Disease Surveillance: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. 1999, Geneva: World Health Organisation Department of Noncommunicable Disease Surveillance
12.
Ernst A, Kinnear M, Hudson S: Quality of prescribing: a study of guideline adherence of medication in patients with diabetes mellitus. Pract Diabetes Int. 2005, 22 (8): 285-290. 10.1002/pdi.850.CrossRef
13.
14.
Members ATF, Rydén L, Standl E, Bartnik M, Berghe GV, Betteridge J, de Boer M-J, Cosentino F, Jönsson B, Laakso M: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: the task force on diabetes and cardiovascular diseases of the european society of cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J Suppl. 2007, 9 (suppl C): C3-C74.CrossRef
15.
American Diabetes Association: Standards of medical care in diabetes-2008. Diabetes Care. 2008, 31 (Suppl 1): S12-S54.CrossRef
16.
National Institute for Health and Clinical Excellence: NICE clinical guideline 43: Obesity. Guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. 2006, London: National Institute for Health and Clinical Excellence
17.
National Institute for Health and Clinical Excellence: NICE clinical guideline 34: Hypertension. Management in Adults in Primary Care. 2006, London: National Institute for Health and Clinical Excellence
18.
National Institute for Health and Clinical Excellence: NICE clinical guideline 48: MI: secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. 2007, London: National Institute for Health and Clinical Excellence
19.
Scottish Intercollegiate Guidelines Network: SIGN Guideline No. 97: Risk estimation and the prevention of cardiovascular disease. 2007, Edinburgh: Scottish Intercollegiate Guidelines Network
20.
Harjutsalo V, Maric C, Forsblom C, Thorn L, Waden J, Groop PH: Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. Diabetologia. 2011, 54 (8): 1992-1999. 10.1007/s00125-011-2144-2.CrossRefPubMed
21.
Ostman J, Lonnberg G, Arnqvist HJ, Blohme G, Bolinder J, Ekbom Schnell A, Eriksson JW, Gudbjornsdottir S, Sundkvist G, Nystrom L: Gender differences and temporal variation in the incidence of type 1 diabetes: results of 8012 cases in the nationwide diabetes incidence study in Sweden 1983–2002. J Intern Med. 2008, 263 (4): 386-394. 10.1111/j.1365-2796.2007.01896.x.CrossRefPubMed
22.
Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G: Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia. 2006, 49 (2): 298-305. 10.1007/s00125-005-0082-6.CrossRefPubMed
23.
Nishimura R, LaPorte RE, Dorman JS, Tajima N, Becker D, Orchard TJ: Mortality trends in type 1 diabetes. The allegheny county (Pennsylvania) registry 1965–1999. Diabetes Care. 2001, 24 (5): 823-827. 10.2337/diacare.24.5.823.CrossRefPubMed
24.
Dawson SI, Willis J, Florkowski CM, Scott RS: All-cause mortality in insulin-treated diabetic patients: a 20-year follow-up. Diabetes Res Clin Pract. 2008, 80 (1): e6-e9. 10.1016/j.diabres.2007.10.033.CrossRefPubMed
25.
Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ: All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the allegheny county type 1 diabetes registry. Diabetes Care. 2010, 33 (12): 2573-2579. 10.2337/dc10-1170.PubMedCentralCrossRefPubMed
26.
Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, Smith AW, Hill RD, Bingley PJ, Patterson CC: The British diabetic association cohort study, I: all-cause mortality in patients with insulin-treated diabetes mellitus. Diabet Med. 1999, 16 (6): 459-465. 10.1046/j.1464-5491.1999.00075.x.CrossRefPubMed
27.
Gavrila D, Salmeron D, Egea-Caparros JM, Huerta JM, Perez-Martinez A, Navarro C, Tormo MJ: Prevalence of metabolic syndrome in Murcia Region, a southern European Mediterranean area with low cardiovascular risk and high obesity. BMC Publ Health. 2011, 11: 562-10.1186/1471-2458-11-562.CrossRef
28.
Valerio G, Iafusco D, Zucchini S, Maffeis C: Abdominal adiposity and cardiovascular risk factors in adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2012, 97 (1): 99-104. 10.1016/j.diabres.2012.01.022.CrossRefPubMed
29.
Rathsman B, Rosfors S, Sjoholm A, Nystrom T: Early signs of atherosclerosis are associated with insulin resistance in non-obese adolescent and young adults with type 1 diabetes. Cardiovasc Diabetol. 2012, 11: 145-10.1186/1475-2840-11-145.PubMedCentralCrossRefPubMed
30.
Dalla Pozza R, Beyerlein A, Thilmany C, Weissenbacher C, Netz H, Schmidt H, Bechtold S: The effect of cardiovascular risk factors on the longitudinal evolution of the carotid intima medial thickness in children with type 1 diabetes mellitus. Cardiovasc Diabetol. 2011, 10: 53-10.1186/1475-2840-10-53.PubMedCentralCrossRefPubMed
31.
Urbina EM, Dabelea D, D’Agostino RB, Shah AS, Dolan LM, Hamman RF, Daniels SR, Marcovina S, Wadwa RP: Effect of type 1 diabetes mellitus on carotid structure and function in adolescents and young adults: the SEARCH CVD study. Diabetes Care. 2013, [Epup ahead of print]
32.
Larkin ME, Backlund JY, Cleary P, Bayless M, Schaefer B, Canady J, Nathan DM: Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabet Med. 2010, 27 (4): 451-458. 10.1111/j.1464-5491.2010.02972.x.CrossRefPubMed
33.
Schwab KO, Doerfer J, Naeke A, Rohrer T, Wiemann D, Marg W, Hofer SE, Holl RW: Influence of food intake, age, gender, HbA1c, and BMI levels on plasma cholesterol in 29,979 children and adolescents with type 1 diabetes–reference data from the German diabetes documentation and quality management system (DPV). Pediatr Diabetes. 2009, 10 (3): 184-192. 10.1111/j.1399-5448.2008.00469.x.CrossRefPubMed
34.
Göbl CS, Bozkurt L, Lueck J, El-Samahi M, Grosser P, Clodi M, Luger A, Kautzky-Willer A: Sex-specific differences in long-term glycemic control and cardiometabolic parameters in patients with type 1 diabetes treated at a tertiary care centre : gender aspects in type 1 diabetes. Wien Klin Wochenschr. 2012, 124 (21–22): 742-749.CrossRefPubMed
35.
Giuffrida FM, Guedes AD, Rocco ER, Mory DB, Dualib P, Matos OS, Chaves-Fonseca RM, Cobas RA, Negrato CA, Gomes MB: Heterogeneous behavior of lipids according to HbA1c levels undermines the plausibility of metabolic syndrome in type 1 diabetes: data from a nationwide multicenter survey. Cardiovasc Diabetol. 2012, 11: 156-10.1186/1475-2840-11-156.PubMedCentralCrossRefPubMed
36.
Wong ND, Glovaci D, Wong K, Malik S, Franklin SS, Wygant G, Iloeje U: Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res. 2012, 9 (2): 146-152. 10.1177/1479164112436403.CrossRefPubMed
37.
Krishnan S, Fields DA, Copeland KC, Blackett PR, Anderson MP, Gardner AW: Sex differences in cardiovascular disease risk in adolescents with type 1 diabetes. Gend Med. 2012, 9 (4): 251-258. 10.1016/j.genm.2012.05.003.PubMedCentralCrossRefPubMed
38.
Shay CM, Secrest AM, Goodpaster BH, Kelsey SF, Strotmeyer ES, Orchard TJ: Regional adiposity and risk for coronary artery disease in type 1 diabetes: does having greater amounts of gluteal-femoral adiposity lower the risk?. Diabetes Res Clin Pract. 2010, 89 (3): 288-295. 10.1016/j.diabres.2010.03.028.PubMedCentralCrossRefPubMed
39.
Ahlgren AR, Sundkvist G, Sandgren T, Lanne T: Female gender increases stiffness of elastic but not of muscular arteries in type I diabetic patients. Clin Physiol Funct Imaging. 2002, 22 (6): 409-415. 10.1046/j.1475-097X.2002.00451.x.CrossRefPubMed
40.
Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M: Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The coronary artery calcification in type 1 diabetes (CACTI) study. Diabetes. 2003, 52 (11): 2833-2839. 10.2337/diabetes.52.11.2833.CrossRefPubMed
41.
Dantas AP, Fortes ZB, de Carvalho MH: Vascular disease in diabetic women: why do they miss the female protection?. Exp Diabetes Res. 2012, 2012: 570598.PubMedCentralCrossRefPubMed
42.
Bolego C, Cignarella A, Zancan V, Pinna C, Zanardo R, Puglisi L: Diabetes abolishes the vascular protective effects of estrogen in female rats. Life Sci. 1999, 64 (9): 741-749. 10.1016/S0024-3205(98)00615-8.CrossRefPubMed
43.
44.
Kaja S, Yang SH, Wei J, Fujitani K, Liu R, Brun-Zinkernagel AM, Simpkins JW, Inokuchi K, Koulen P: Estrogen protects the inner retina from apoptosis and ischemia-induced loss of Vesl-1L/Homer 1c immunoreactive synaptic connections. Invest Ophthalmol Vis Sci. 2003, 44 (7): 3155-3162. 10.1167/iovs.02-1204.CrossRefPubMed
45.
Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998, 105 (10): 1801-1815. 10.1016/S0161-6420(98)91020-X.CrossRefPubMed
46.
van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, Kofinis A, Rottiers R, Porta M, Chaturvedi N: Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care. 2005, 28 (6): 1383-1389. 10.2337/diacare.28.6.1383.CrossRefPubMed
47.
Hammes HP, Kerner W, Hofer S, Kordonouri O, Raile K, Holl RW: Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients. Diabetologia. 2011, 54 (8): 1977-1984. 10.1007/s00125-011-2198-1.CrossRefPubMed
48.
Kubin M, Tossavainen P, Hannula V, Lahti S, Hautala N, Falck A: Prevalence of retinopathy in Finnish children and adolescents with type 1 diabetes: a cross-sectional population-based retrospective study. Arch Dis Child. 2011, 96 (10): 963-968. 10.1136/adc.2011.210807.CrossRefPubMed
49.
Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH: Prevalence of complications in IDDM by sex and duration. Pittsburgh epidemiology of diabetes complications study II. Diabetes. 1990, 39 (9): 1116-1124. 10.2337/diabetes.39.9.1116.CrossRefPubMed
50.
Chaurasia RK, Singh R, Agrawal JK, Maurya OP: Sex hormones and diabetic retinopathy. Ann Ophthalmol. 1993, 25 (6): 227-230.PubMed
51.
Polak JF, Backlund JY, Cleary PA, Harrington AP, O’Leary DH, Lachin JM, Nathan DM: Progression of carotid artery intima-media thickness during 12 years in the diabetes control and complications Trial/Epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes. 2011, 60 (2): 607-613. 10.2337/db10-0296.PubMedCentralCrossRefPubMed
52.
Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E: Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005, 28 (3): 514-520. 10.2337/diacare.28.3.514.CrossRefPubMed
53.
de Pablos-Velasco P, Parhofer KG, Bradley C, Eschwege E, Gonder-Frederick L, Maheux P, Wood I, Simon D: Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2012, [Epup ahead of print]
Metadata
Title
Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study
Authors
Alexandra Kautzky-Willer
Kathrin Stich
Juliane Hintersteiner
Alexander Kautzky
Majid Reza Kamyar
Johannes Saukel
Julienne Johnson
Rosa Lemmens-Gruber
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-78

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue

Original investigation

Accumulation of epicardial fat rather than visceral fat is an independent risk factor for left ventricular diastolic dysfunction in patients undergoing peritoneal dialysis

Original investigation

Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects

Original investigation

Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients

Original investigation

Low-grade albuminuria is associated with early but not late carotid atherosclerotic lesions in community-based patients with type 2 diabetes

Original investigation

Arg972 Insulin receptor substrate-1 is associated with decreased serum angiotensin-converting enzyme 2 levels in acute myocardial infarction patients: in vivo and in vitro evidence

Original investigation

Insulin resistance is significantly associated with the metabolic syndrome, but not with sonographically proven peripheral arterial disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits